Unmasking the dynamic interplay between efflux transporters and metabolic enzymes

被引:190
作者
Benet, LZ [1 ]
Cummins, CL [1 ]
Wu, CY [1 ]
机构
[1] Univ Calif San Francisco, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA
关键词
P-glycoprotein; CYP3A4; transport; metabolism; Caco-2; cells; tacrolimus; sirolimus; midazolam; felodipine; sex differences;
D O I
10.1016/j.ijpharm.2002.12.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Drug efflux by intestinal P-glycoprotein (P-gp) is known to decrease the bioavailability of many CYP3A4 substrates. We have demonstrated that vie interplay between P-gp and CYP3A4 at the apical intestinal membrane can increase the opportunity for drug metabolism by determining bidirectional extraction ratios across CYP3A4-transfected Caco-2 cells for two dual P-gp/CYP3A4 substrates, K77 (an experimental cysteine protease inhibitor) and sirolimus, as well as two negative control, CYP3A4 only substrates, midazolam and felodipine. Studies were carried out under control conditions, with a P-gp inhibitor (GG918) and with a dual inhibitor (cyclosporine). Measurement of intracellular concentration changes is an important component in calculating the extraction ratios. We hypothesize that the inverse orientation of P-gp and CYP3A4 in the liver will result in an opposite interactive effect in that organ. In vivo rat intestinal perfusion studies with K77 and rat liver perfusion studies with tacrolimus under control conditions and with inhibitors of CYP3A4 (troleandomycin), P-gp (GG918) and both CYP3A4/P-gp (cyclosporine) lend support to our hypotheses. These results serve as a template for predicting enzyme-transporter (both absorptive and efflux) interactions in the intestine and the liver. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:3 / 9
页数:7
相关论文
共 23 条
[1]   Intestinal drug absorption and metabolism in cell cultures: Caco-2 and beyond [J].
Artursson, P ;
Borchardt, RT .
PHARMACEUTICAL RESEARCH, 1997, 14 (12) :1655-1658
[2]   Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery [J].
Benet, LZ ;
Wu, CY ;
Hebert, MF ;
Wacher, VJ .
JOURNAL OF CONTROLLED RELEASE, 1996, 39 (2-3) :139-143
[3]   The drug efflux-metabolism alliance: biochemical aspects [J].
Benet, LZ ;
Cummins, CL .
ADVANCED DRUG DELIVERY REVIEWS, 2001, 50 :S3-S11
[4]   Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4 [J].
Cummins, CL ;
Jacobsen, W ;
Benet, LZ .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 300 (03) :1036-1045
[5]   In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: Studies using the rat single-pass intestinal perfusion model [J].
Cummins, CL ;
Salphati, L ;
Reid, MJ ;
Benet, LZ .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 305 (01) :306-314
[6]   Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein [J].
Cummins, CL ;
Wu, CY ;
Benet, LZ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (05) :474-489
[7]   Characterizing the expression of CYP3A4 and efflux transporters (P-gp, MRP1, and MRP2) in CYP3A4-transfected Caco-2 cells after induction with sodium butyrate and the phorbol ester 12-O-tetradecanoylphorbol-13-acetate [J].
Cummins, CL ;
Mangravite, LM ;
Benet, LZ .
PHARMACEUTICAL RESEARCH, 2001, 18 (08) :1102-1109
[8]  
Fisher JM, 1999, J PHARMACOL EXP THER, V289, P1134
[9]   Evidence for different ABC-transporters in Caco-2 cells modulating drug uptake [J].
Gutmann, H ;
Fricker, G ;
Török, M ;
Michael, S ;
Beglinger, C ;
Drewe, J .
PHARMACEUTICAL RESEARCH, 1999, 16 (03) :402-407
[10]  
HAMILTON RL, 1974, J LIPID RES, V15, P182